Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017
Latest news articles
Added 25 days ago Drug news
European Commission approves Imraldi, a biosimilar referencing Humira (adalimumab) to treat the originator drug indications- Biogen.
Samsung Bioepis Co., Ltd. announced the European Commission’s (EC) approval of Imraldi, a biosimilar referencing Humira (adalimumab), for the treatment...
Added 4 months ago Drug news
EU CHMP recommends approval of Oxervate (cenegermin) in moderate to severe neurotrophic keratitis- Dompé
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
Added 7 months ago Drug news
EU CHMP recommends approval of Amgevita (adalimumab biosimilar) for rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis and uveiti-Amgen
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Fluid Management
Are you up-to-date with the latest evidence of effective procedures for fluid management?
Type 2 Diabetes
View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more.
CME
Measles: clinical review
- Accrediting body
-
MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- 1
- Registration required
- 0
- Subscription fee
- 0
Eczema in children: management and advice for parents
- Accrediting body
-
MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- 0
- Registration required
- 1
- Subscription fee
- 15
Chickenpox (varicella zoster): clinical review
- Accrediting body
-
MIMS Learning - Monthly Index of Medical Specialities
- Credits available
- 2
- Registration required
- 1
- Subscription fee
- 0